Literature DB >> 30843164

Impact of Anatomical Versus Non-anatomical Liver Resection on Short- and Long-Term Outcomes for Patients with Intrahepatic Cholangiocarcinoma.

Anfeng Si1,2, Jun Li1, Zhishi Yang1, Yong Xia1,3, Tian Yang1, Zhengqing Lei1, Zhangjun Cheng1,4, Timothy M Pawlik5, Wan Yee Lau1,6, Feng Shen7.   

Abstract

OBJECTIVE: The aim of this study was to examine the impact of anatomical resection (AR) versus non-anatomical resection (NAR) on the survival outcomes in patients with intrahepatic cholangiocarcinoma (ICC). PATIENTS AND METHODS: Data on 702 consecutive patients who underwent either AR (n = 319) or NAR (n = 383) for ICC were reviewed. Disease-free survival (DFS) and overall survival (OS) following AR versus NAR was compared using propensity score matching (PSM). Subgroups of patients who benefited from AR versus NAR were examined after being stratified by the 8th TNM staging of ICC.
RESULTS: AR and NAR had similar complication rates (26.6% vs. 25.1%, p = 0.634). AR was associated with better 1-, 3-, and 5-year DFS and OS rates compared with NAR after PSM (58.1%, 35.7% and 28.1% vs. 44.1%, 23.9% and 18.0%; 72.9%, 45.7% and 36.0% vs. 62.0%, 30.8% and 25.3%; both p = 0.002). On multivariate analysis, NAR was associated with worse DFS and OS than AR [hazard ratio (HR) 1.461 and 1.488; 95% confidence interval (CI) 1.184-1.804 and 1.189-1.863, respectively]. Stratified analysis demonstrated similar outcomes following AR versus NAR for ICC at stages IA, II with vascular invasion, and III with visceral peritoneum perforation, local extrahepatic invasion and nodal metastasis, while NAR was associated with worse DFS and OS versus AR for stages IB (HR 1.897 and 2.321; 95% CI 1.179-3.052 and 1.376-3.914, respectively) or II ICC without vascular invasion (2.071 and 2.077; 95% CI 1.239-3.462 and 1.205-3.579, respectively).
CONCLUSIONS: AR was associated with better survival outcomes compared with NAR in ICC patients with stage IB or II tumors without vascular invasion.

Entities:  

Mesh:

Year:  2019        PMID: 30843164     DOI: 10.1245/s10434-019-07260-8

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  12 in total

Review 1.  [Cholangiocarcinoma-Intrahepatic to hilar bile duct cancer].

Authors:  Sebastian Rademacher; Timm Denecke; Thomas Berg; Daniel Seehofer
Journal:  Chirurgie (Heidelb)       Date:  2022-06-13

Review 2.  The focus clinical research in intrahepatic cholangiocarcinoma.

Authors:  Yinghui Song; Mengting Cai; Yuhang Li; Sulai Liu
Journal:  Eur J Med Res       Date:  2022-07-11       Impact factor: 4.981

3.  The Landmark Series: Intrahepatic Cholangiocarcinoma.

Authors:  Jordan M Cloyd; Aslam Ejaz; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2020-05-17       Impact factor: 5.344

4.  Surgical management of biliary malignancy.

Authors:  T Peter Kingham; Victoria G Aveson; Alice C Wei; Jason A Castellanos; Peter J Allen; Daniel P Nussbaum; Yinin Hu; Michael I D'Angelica
Journal:  Curr Probl Surg       Date:  2020-06-30       Impact factor: 1.909

Review 5.  Cholangiocarcinoma as an Indication for Liver Transplantation in the Era of Transplant Oncology.

Authors:  Enrico Gringeri; Martina Gambato; Gonzalo Sapisochin; Tommy Ivanics; Erica Nicola Lynch; Claudia Mescoli; Patrizia Burra; Umberto Cillo; Francesco Paolo Russo
Journal:  J Clin Med       Date:  2020-05-05       Impact factor: 4.241

6.  The diagnostic and prognostic value of UBE2T in intrahepatic cholangiocarcinoma.

Authors:  Hua Yu; Han Wang; Wei Dong; Zhen-Ying Cao; Rong Li; Chao Yang; Wen-Ming Cong; Hui Dong; Guang-Zhi Jin
Journal:  PeerJ       Date:  2020-01-27       Impact factor: 2.984

7.  Current management of intrahepatic cholangiocarcinoma: from resection to palliative treatments.

Authors:  Ilenia Bartolini; Matteo Risaliti; Laura Fortuna; Carlotta Agostini; Maria Novella Ringressi; Antonio Taddei; Paolo Muiesan
Journal:  Radiol Oncol       Date:  2020-07-29       Impact factor: 2.991

Review 8.  The Role of Surgical Resection and Liver Transplantation for the Treatment of Intrahepatic Cholangiocarcinoma.

Authors:  Guergana Panayotova; Jarot Guerra; James V Guarrera; Keri E Lunsford
Journal:  J Clin Med       Date:  2021-05-30       Impact factor: 4.241

Review 9.  The new insight of treatment in Cholangiocarcinoma.

Authors:  Yuhang Li; Yinghui Song; Sulai Liu
Journal:  J Cancer       Date:  2022-01-01       Impact factor: 4.207

Review 10.  Treatment of Intrahepatic Cholangiocarcinoma-A Multidisciplinary Approach.

Authors:  Felix Krenzien; Nora Nevermann; Alina Krombholz; Christian Benzing; Philipp Haber; Uli Fehrenbach; Georg Lurje; Uwe Pelzer; Johann Pratschke; Moritz Schmelzle; Wenzel Schöning
Journal:  Cancers (Basel)       Date:  2022-01-12       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.